169 related articles for article (PubMed ID: 38111506)
1. Tenofovir amibufenamide
Peng WT; Jiang C; Yang FL; Zhou NQ; Chen KY; Liu JQ; Peng SF; Fu L
World J Gastroenterol; 2023 Nov; 29(44):5907-5918. PubMed ID: 38111506
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues].
Sheng QJ; Han C; Li YW; Zhang C; Dou XG; Ding Y
Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):252-257. PubMed ID: 37137850
[No Abstract] [Full Text] [Related]
3. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study.
Li L; Zhou J; Li Y; Wang F; Zhang D; Wang M; Tao Y; Chen E
Front Pharmacol; 2023; 14():1165990. PubMed ID: 37324480
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Lim J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
Liver Int; 2022 Jul; 42(7):1517-1527. PubMed ID: 35343041
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
6. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L
World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775
[TBL] [Abstract][Full Text] [Related]
7. One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
Chen YC; Hsu CW; Chien RN; Tai DI
Medicine (Baltimore); 2022 Jun; 101(25):e29269. PubMed ID: 35758355
[TBL] [Abstract][Full Text] [Related]
8. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
9. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
10. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Hsu YC; Wei MT; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
13. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Jeong J; Shin JW; Jung SW; Park EJ; Park NH
Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
Liu R; Qiao J; Zhang L; Dou Z
Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Viganò M; Loglio A; Grossi G; Lampertico P
Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
Kim JH; Jung SW; Byun SS; Shin JW; Park BR; Kim MH; Kim CJ; Park NH
Int J Clin Pharm; 2015 Dec; 37(6):1228-34. PubMed ID: 26364195
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B.
Liu Z; Jin Q; Zhang Y; Gong G; Wu G; Yao L; Wen X; Gao Z; Huang Y; Yang D; Chen E; Mao Q; Lin S; Shang J; Gong H; Zhong L; Yin H; Wang F; Hu P; Xiao L; Li C; Wu Q; Sun C; Niu J; Hou J;
Aliment Pharmacol Ther; 2021 Nov; 54(9):1134-1149. PubMed ID: 34587302
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
Zeng QL; Zhang HX; Zhang JY; Huang S; Li WZ; Li GM; Pan YJ; Feng YH; Li ZQ; Zhang GF; Xu JH; Lin WB; Xu GH; Liu N; Zhang GQ; Li GT; Li W; Zeng YL; Song N; Wang M; Zhang DW; Chen ZM; Cui GL; Li J; Lv J; Liu YM; Liang HX; Sun CY; Zhou YH; Yu ZJ; Wang FS
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2826-2837.e9. PubMed ID: 34902570
[TBL] [Abstract][Full Text] [Related]
20. Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Jung CY; Kim HW; Lee JI; Lee HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 Nov; 42(11):2408-2417. PubMed ID: 35943853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
